http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
누에나방(Bombyx moriL.) 번데기 분말 섭취와 저항성 운동훈련에 의한 에너지 대사에 미치는 영향
손진화(Son, Jin-Hwa),김이슬(Kim, Yi-Seul),김경환(Kim, Kyung-Hwan),전병덕(Jeon, Byung-Duk),권태동(Kwon, Tae-Dong) 한국체육과학회 2018 한국체육과학회지 Vol.27 No.5
The purpose of this study is to observe the silkworm pupa powder ingestion with/without resistance exercise training for energy metabolism in ICR mouse. For this purpose, four different diet groups (28 ICR mouse were grouped as the control diet group CON, the control diet resistance exercise group CORE, the silkworm pupae diet group SPD and silkworm pupa diet resistance exercise group SPRE n=7) were used. The amounts of fat mass were decreased in SPD and SPRE than CON. In addition, it was also significantly difference between the groups (p<.05). However, GLUT-2 protein expression didn’t show any significant differences between the groups. GLUT-4 protein expression showed significantly increased in SPRE group (p<.05). AMPK protein expression was also increased in SPRE compared with to CON (p<.05). FNDC5 protein expression didn’t show any significant differences between the groups. These results suggested that silkworm pupa powder ingestion and resistance exercise was affected by the energy metabolism because of high protein, linoleic acid and linolenic acid are abundant in silkworm pupa. Also, silkworm pupa can be used to improve energy metabolism in body. It is considered that the effect of edible insects can be proved as scientific basic data for the activation of edible insect industry.
김연아 ( Yeona Kim ),하대룡 ( Dae-lyong Ha ),손진화 ( Jin-hwa Son ),신기혁 ( Kihyuk Shin ),이정수 ( Jungsoo Lee ),김훈수 ( Hoon-soo Kim ),고현창 ( Hyun-chang Ko ),김병수 ( Byung Soo Kim ),김문범 ( Moon-bum Kim ) 대한피부과학회 2020 大韓皮膚科學會誌 Vol.58 No.9
A poroma is a benign adnexal neoplasm originating from the sweat gland duct. It usually presents clinically as a soft erythematous or flesh-colored papule, plaque, or nodule on the palms and soles. In most cases, poromas manifest as a solitary lesion, but rarely, multiple lesions have been reported and are defined as poromatosis. Although the pathogenesis is unclear, poromatosis is known to be associated with actinic damage, human papillomavirus infection, radiation therapy, or polychemotherapy. Herein, we describe a 53-year-old woman who had multiple erythematous papules on her feet for a year. She had a medical history of acute lymphoblastic leukemia and had undergone polychemotherapy with stem cell transplantation. To our knowledge, poromatosis related to chemotherapy is a rare entity, and our case could be attributed to the theory that using polychemotherapy can induce poromatosis. (Korean J Dermatol 2020;58(9):617∼619)
중등도-중증의 한국인 건선 환자에서 Ustekinumab 장기 투여에 따른 효과 및 안전성 연구
김연아 ( Yeona Kim ),배경남 ( Kyung-nam Bae ),손진화 ( Jin-hwa Son ),신기혁 ( Kihyuk Shin ),김훈수 ( Hoonsoo Kim ),고현창 ( Hyun-chang Ko ),김문범 ( Moon-bum Kim ),신봉석 ( Bong Seok Shin ),김병수 ( Byungsoo Kim ) 대한피부과학회 2022 대한피부과학회지 Vol.60 No.3
Background: Ustekinumab is a humanized monoclonal antibody targeting interleukin (IL)-12 and IL-23. Although popular, data on its long-term efficacy and safety in Korean patients with psoriasis are limited. Objective: To evaluate the long-term efficacy and safety of ustekinumab in Korean patients with psoriasis. Methods: A retrospective study in patients with moderate-to-severe psoriasis who had been treated with ustekinumab for at least 5 years was conducted. The sex, age, body mass index, medical records, previous psoriasis therapy, psoriasis area and severity index (PASI) scores, and adverse events were evaluated. Results: Twenty-five patients (median age 47.00 years) had been treated with ustekinumab for 5 years. The mean duration of psoriasis was 19.12±8.45 years, and the treatment duration with ustekinumab was 285.12±8.48 weeks. The baseline PASI was 17.52±7.38. PASI75 was achieved in 84% of the patients at week 28, and 96% of the patients maintained PASI75 during the 5-year follow-up period. Furthermore, 56% of patients reached PASI90 at 28 weeks, and 48% of patients maintained PASI90 for 5 years. No unexpected adverse events other than herpes zoster, herpes simplex, or elevated liver enzymes were reported. Conclusion: Ustekinumab demonstrated long-lasting efficacy with an acceptable safety profile in Korean patients with moderate-to-severe psoriasis. (Korean J Dermatol 2022;60(3):151∼158)
김연아 ( Yeona Kim ),하대룡 ( Dae-lyong Ha ),손진화 ( Jin-hwa Son ),신기혁 ( Kihyuk Shin ),이정수 ( Jungsoo Lee ),김훈수 ( Hoon-soo Kim ),고현창 ( Hyun-chang Ko ),김병수 ( Byung Soo Kim ),김문범 ( Moon-bum Kim ) 대한피부과학회 2020 大韓皮膚科學會誌 Vol.58 No.9
Background: Tumoral calcinosis is characterized by the deposition of calcific masses around major joints, and it often causes significant impairment of joint function. Dermatologists sometimes encounter patients with a subcutaneous hard mass around the joint. However, there are few studies about tumoral calcinosis in the dermatologic literature, especially in Korea. Objective: The aim of this study was to determine the clinical characteristics of tumoral calcinosis. Methods: We reviewed the clinical photographs, medical records, and biopsy specimens of 11 cases of tumoral calcinosis seen at our clinic in 10 years. Results: All 11 patients were female, and the mean age at onset was 58.5 years. The mean duration of the disease was 7.1 years. Most patients (9, 81.8%) presented with an asymptomatic subcutaneous hard mass around the iliac crest. None of the patients had a family history, or abnormal serum calcium, phosphorus, and parathyroid hormone levels. All patients underwent surgery for treatment. Conclusion: Tumoral calcinosis can occur sporadically without metabolic disease. Therefore, careful history taking and biochemical work-up involving the metabolism of calcium and phosphorus should be performed. If there is no peculiarityon examination, the lesion is cured by resection. Although the sample size of this study is small, it can be inferred that the characteristics of tumoral calcinosis in Korea can be described by its predominant sex preponderance and location, that is, the female sex and the iliac crest, respectively. (Korean J Dermatol 2020;58(9):596∼600)
Cyclosporine 저항성 만성 자발성 두드러기환자에서 Omalizumab 치료에 대한 단일기관 후향적 연구
김학준 ( Hak-jun Kim ),김우일 ( Woo-il Kim ),신기혁 ( Kihyuk Shin ),손진화 ( Jin-hwa Son ),이원구 ( Won-ku Lee ),김훈수 ( Hoon-soo Kim ),김병수 ( Byungsoo Kim ),김문범 ( Moon-bum Kim ),고현창 ( Hyun-chang Ko ) 대한피부과학회 2021 대한피부과학회지 Vol.59 No.3
Background: Cyclosporine is a recommended third-line treatment for chronic spontaneous urticaria (CSU) that is resistant to H1-antihistamines according to the EAACI/GA<sup>2</sup>LEN/EDF/WAO guidelines for management of urticaria. However, some patients with refractory urticaria do not respond to cyclosporine or antihistamines. Omalizumab, a humanized anti-immunoglobulin E antibody, has been shown to be effective and safe for antihistamine-resistant CSU. However, there are few reports on the efficacy of omalizumab in patients with CSU who are resistant to cyclosporine. Objective: To evaluate the efficacy of omalizumab in patients with cyclosporine-resistant CSU. Methods: Recalcitrant CSU patients who had symptoms (seven-day urticaria activity score, UAS7≥7) despite being administered cyclosporine (3∼5 mg/kg/day) and H1-antihistamine at up to a four-fold increased dose for 4 weeks were included in this study. Omalizumab was administered at 150 mg or 300 mg by subcutaneous injection every 4 weeks. Efficacy was assessed using UAS7 12 weeks after the initial administration of omalizumab. Results: A total of 28 patients (18 women, 10 men) with an average age of 43.8 years were included in the study. The mean duration of CSU was 40.0 (2∼288) months, and the mean UAS7 at baseline was 14.2 (9∼35) months. Overall, 22 patients (78.6%) showed a complete (UAS7=0) or partial response (0<UAS7≤6) at 12 weeks. Patients who were administered 300 mg of omalizumab had a more complete response (9/15, 60%) than those who were treated with 150 mg (3/13, 23.1%). Conclusion: Omalizumab is an effective therapy for CSU patients who do not respond to cyclosporine. (Korean J Dermatol 2021;59(3):175∼180)
소아 피부근염의 임상적 특징과 예후: 후향적 연구 및 문헌 고찰
김태림 ( Tae-rim Kim ),배경남 ( Kyung-nam Bae ),손진화 ( Jin-hwa Son ),신기혁 ( Kihyuk Shin ),김훈수 ( Hoon-soo Kim ),고현창 ( Hyun-chang Ko ),김문범 ( Moon-bum Kim ),김병수 ( Byung-soo Kim ) 대한피부과학회 2021 대한피부과학회지 Vol.59 No.9
Background: Juvenile dermatomyositis (JDM) is a rare but common childhood idiopathic inflammatory myopathy. Proximal muscle weakness and pathognomonic skin rash, Gottron papules, and heliotrope rash are characteristic clinical features of JDM. However, clinical analysis of JDM has rarely been reported in the Korean dermatologic literature. Objective: This study aimed to investigate the clinical features and outcomes of JDM in Korea and previous studies. Methods: We retrospectively reviewed the medical records and clinical photographs of patients diagnosed with JDM at Pusan National University Hospital (Busan and Yangsan) for 17 years (2005∼2021). Results: We encountered 12 patients with JDM (male to female ratio=7:5) with a mean age of 7.2 years. The most common clinical features were Gottron papules (100%), followed by Gottron sign (83.3%), malar rash (58.3%), heliotrope rash (41.7%), shawl sign (16.7%), calcinosis cutis (8.3%), and ulcer (8.3%). In all cases, there was no concurrent interstitial lung disease or an underlying malignancy. Only 1 of 12 patients complained of proximal muscle weakness, and four patients showed an increase in muscle enzymes in the laboratory test. The skin lesions gradually improved after systemic steroid or topical treatment in all cases. No additional proximal muscle weakness was found during the follow-up. Conclusion: Although proximal muscle weakness is a common symptom in JDM, clinically amyopathic JDM is commonly found in dermatologic clinics. Regardless of subtype, all patients responded well to treatment and rarely encountered recurrence. (Korean J Dermatol 2021;59(9):699∼706)
Brentuximab Vedotin로 치료한 CD30 양성 대세포 이행을 보인 균상식육종 1예
신준오 ( Jun-oh Shin ),배경남 ( Kyung-nam Bae ),손진화 ( Jin-hwa Son ),신기혁 ( Kihyuk Shin ),김훈수 ( Hoon-soo Kim ),고현창 ( Hyun-chang Ko ),김문범 ( Moon-bum Kim ),김병수 ( Byungsoo Kim ) 대한피부과학회 2022 대한피부과학회지 Vol.60 No.2
Large-cell transformation of mycosis fungoides (LCT-MF) is an advanced stage of primary cutaneous T-cell lymphoma with a poor prognosis. Therapeutic options for these patients are often limited, and so far, they are not promising. An 81-year-old woman with a previous history of mycosis fungoides presented with aggravation of generalized erythematous scaly patches and new onset of ulcerated tumor on the abdomen for 3 months. Histopathological examination revealed a dense dermal infiltrate composed of atypical large lymphocytes. Immunohistochemically, the tumor cells were positive for CD30 expression. A diagnosis of CD30<sup>+</sup> LCT-MF was established. She was intensively treated with methotrexate (1 month), acitretin (1 month), and rituximab with dose-modified cyclophosphamide, doxorubicin, and prednisone (1 cycle). Despite such treatments, the improvement was minimal. Subsequently, the patient was started on brentuximab vedotin, 1.8 mg/kg intravenously once every 3 weeks. She responded well to brentuximab therapy, and the skin lesions completely subsided within 12 weeks of treatment. (Korean J Dermatol 2022;60(2):106∼110)